Literature DB >> 11318785

A novel homozygous mutation in the second transmembrane domain of the gonadotrophin releasing hormone receptor gene.

D Söderlund1, P Canto, E de la Chesnaye, A Ulloa-Aguirre, J P Méndez.   

Abstract

BACKGROUND AND
OBJECTIVE: Mutations in the GnRH receptor (GnRH-R) gene cause hypogonadotrophic hypogonadism. Here, we present the molecular studies of the GnRH-R gene in three families with isolated hypogonadotrophic hypogonadism. PATIENTS: Three unrelated families, with at least two members diagnosed with isolated hypogonadotrophic hypogonadism were included. MEASUREMENTS: DNA sequencing was performed after polymerase chain reaction amplification of each of the three exons of the gene.
RESULTS: A novel homozygous missense mutation, at nucleotide 268, turning glutamic acid into lysine, located at the second transmembrane domain of the GnRH-R gene was found in two patients pertaining to one of the families studied. Both parents and an unaffected brother were heterozygous carriers of one mutant allele, an unaffected sister was homozygote wild type. In the other two affected families no mutations were found in the GnRH-R gene.
CONCLUSIONS: This constitutes the first description of an spontaneous mutation located at the second transmembrane domain (Glu90Lys) of the GnRH-R, indicating that the integrity of glutamic acid at this position is crucial for receptor function. Also this report, complementing others, demonstrates that mutations are distributed throughout the GnRH-R gene and that as in the only other homozygous mutation previously described, affected patients present a complete form of hypogonadotrophic hypogonadism. Due to the fact that apparently consanguinity was present in our affected family, we presume that the mutation derived from a common ancestor, by a founder gene effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318785     DOI: 10.1046/j.1365-2265.2001.01211.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

Review 2.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

Review 3.  Familial normosmic idiopathic hypogonadotropic hypogonadism: is there a phenotypic marker for each genetic mutation? Report of three cases and review of literature.

Authors:  Shashank Shekhar
Journal:  BMJ Case Rep       Date:  2012-12-10

Review 4.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 5.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 6.  Genotype and phenotype of patients with gonadotropin-releasing hormone receptor mutations.

Authors:  Hyung-Goo Kim; Jennifer Pedersen-White; Balasubramanian Bhagavath; Lawrence C Layman
Journal:  Front Horm Res       Date:  2010-04-08       Impact factor: 2.606

7.  Computational Analysis of Missense Variants of G Protein-Coupled Receptors Involved in the Neuroendocrine Regulation of Reproduction.

Authors:  Le Min; Min Nie; Anna Zhang; Junping Wen; Sekoni D Noel; Vivian Lee; Rona S Carroll; Ursula B Kaiser
Journal:  Neuroendocrinology       Date:  2015-06-18       Impact factor: 4.914

8.  Mice harboring Gnrhr E90K, a mutation that causes protein misfolding and hypogonadotropic hypogonadism in humans, exhibit testis size reduction and ovulation failure.

Authors:  M David Stewart; Jian Ming Deng; C Allison Stewart; Rachael D Mullen; Ying Wang; Suhujey Lopez; M Katalina Serna; Cheng-Chiu Huang; Jo Ann Janovick; Andrew J Pask; Robert J Schwartz; P Michael Conn; Richard R Behringer
Journal:  Mol Endocrinol       Date:  2012-08-23

9.  A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

Authors:  P Michael Conn; Emery Smith; Timothy Spicer; Peter Chase; Louis Scampavia; Jo Ann Janovick
Journal:  Assay Drug Dev Technol       Date:  2014-05       Impact factor: 1.738

Review 10.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.